Clinical trial
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally…
NCT00077519 · Abramson Cancer Center at Penn Medicine, Other · Completed
Key facts
| NCT number | NCT00077519 |
|---|---|
| Title | Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer |
| Official title | A Phase I Trial of the Farnesyltransferase Inhibitor, R115777 (NSC# 702818) and Radiotherapy in Patients With Locally Advanced Pancreatic Cancer |
| Lead sponsor | Abramson Cancer Center at Penn Medicine, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug, Radiation |
| Interventions | tipifarnib, radiation therapy |
| Enrollment | 18 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 31, 2019 |
| Completion | Dec 31, 2019 |
| First posted | Feb 12, 2004 |
| Last update posted | Apr 15, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: